Report: Bioprocessing trends 2018-2023
According to Mike Ultee of Ulteemit Bioconsulting, the bioprocessing industry should prepare for a number of growing trends in the development and manufacture of biologics. Among the predictions, cited in the CPhI Worldwide Annual Report, are improved productivity of fusion proteins and enzymes, and the rise of continuous bioprocessing.
Chimeric antigen receptor (CAR) T-cell therapy pipelines will continue to advance towards commercialisation, said Ultee.
“In five years’ time, we will have been through a golden period, with game-changing improvements made in upstream, downstream and continuous bioprocessing.
“The market will by then also boast much greater numbers of biosimilars and new applications for cell and gene therapies. The industry is collectively maturing extremely quickly from big pharma and biosimilars to contract development and manufacturing organisations (CDMOs),” he added.
